NFKB1 and carcinoma: Although activating mutations in the NF-κB signaling pathway are common in many lymphoid malignancies, they are rare in carcinomas (DiDonato et al. 2012); suggesting that NF-κB activation in solid tumors is driven in large part by extrinsic factors (Mantovani et al. 2008).